Channel Therapeutics Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CHRO research report →
Companychanneltherapeutics.com
Channel Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1. 7, as well as other receptors in the NaV family.
- CEO
- Francis Knuettel II,
- IPO
- 2024
- Employees
- 4
- HQ
- Freehold, NJ, US
Price Chart
Valuation
- Market Cap
- $8.90M
- P/E
- -0.59
- P/S
- 0.53
- P/B
- 0.65
- EV/EBITDA
- -0.56
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -2.31%
- Op Margin
- -143.51%
- Net Margin
- -257.93%
- ROE
- -200.45%
- ROIC
- -19.72%
Growth & Income
- Revenue
- $16.80M · 0.00%
- Net Income
- $-43,319,000 · -444.53%
- EPS
- $-23.04 · -1511.19%
- Op Income
- $0
- FCF YoY
- -291.70%
Performance & Tape
- 52W High
- $54.29
- 52W Low
- $1.23
- 50D MA
- $12.03
- 200D MA
- $12.00
- Beta
- 3.29
- Avg Volume
- 111.31K
Get TickerSpark's AI analysis on CHRO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 11, 25 | Simmons Chia-Lin | other | 25,000 |
| Apr 11, 25 | Francis Knuettel II | other | 53,988 |
| Nov 13, 24 | Davis Todd C | other | 49,605 |
| Nov 13, 24 | Malamut Richard | other | 24,533 |
| Nov 13, 24 | Friedberg Ezra M | other | 24,533 |
| Sep 12, 24 | Malamut Richard | buy | 10,400 |
| Sep 13, 24 | Francis Knuettel II | buy | 3,500 |
| Sep 12, 24 | Francis Knuettel II | buy | 1,700 |
| Sep 11, 24 | Francis Knuettel II | buy | 5,500 |
| Sep 10, 24 | Francis Knuettel II | buy | 6,500 |
Our CHRO Coverage
We haven't published any research on CHRO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CHRO Report →